Identification of signalling cascades involved in cardiomyogenesis is crucial for optimising the generation of cardiomyocytes from embryonic stem cells (ES cells) in vitro. We used a transgenic ES cell lineage expressing enhanced green fluorescent protein (EGFP) under the control of the α-myosin heavy chain (α-MHC) promoter (pαMHC-EGFP) to investigate the effects of 33 small molecules interfering with several signalling cascades on cardiomyogenesis. Interestingly, the L-Type Ca 2+
Introduction
Embryonic stem cells (ES cells) isolated from the inner cell mass of early blastocyst-stage embryos are pluripotent [1] , possessing the unique property to 304 differentiate in vitro into any somatic cell type, including cardiomyocytes, haematopoietic progenitors, skeletal myocytes, smooth muscle cells, adipocytes, chondrocytes, endothelial cells, neurons and glia, and pancreatic islet cells [2] . When cultured in the presence of leukaemia inhibitory factor (LIF), murine ES cells remain undifferentiated and can be propagated indefinitely [1, 3] . Upon withdrawal of LIF, ES cells spontaneously and irreversibly differentiate into multicellular aggregates, socalled embryoid bodies (EBs). These aggregates resemble early post-implantation embryos and contain derivatives of all three germ layers (for review see [4] ). ES cells may offer an unlimited source of diverse somatic cells for potential clinical applications of various degenerative disorders such as myocardial infarction, Parkinson's disease, diabetes and hepatitis. Additionally, ES cellderived cell types and tissues can be used to establish cell-based in vitro test systems for drug screening, toxicity testing, and functional analysis.
Applying appropriate culture conditions allows generation of cardiomyocytes from ES cells in vitro. The process of cardiomyogenesis involves differentiation, proliferation, and migration of early cardiomyocytes. Identifying soluble factors and signal cascades involved in cardiomyogenesis is crucial for optimising the generation of cardiomyocytes in vitro and understanding cardiac development in vivo.
In this context, experimental models are required allowing rapid and "easy-to-handle" parallel testing of small molecules which may influence the differentiation of ES cells towards cardiomyocytes. For this aim we used a transgenic ES cell lineage expressing enhanced green fluorescent protein (EGFP) under the control of α-myosin heavy chain (α-MHC) promoter (pαMHC-EGFP), allowing us to investigate 33 small molecules (see table  1 ) interfering with various cellular signalling cascades on cardiomyogenesis in ES cells. As shown by Kolossov et al. [5] , expression of EGFP in the cell line used correlated with appearance of other cardiac markers, and can therefore be used to quantify the amount of cardiac cells within the differentiated EB.
Materials and Methods

Materials
Except Serotonin, TTX, Ganglioside GM1 and Testosteron that have been obtained from Sigma-Aldrich Chemie GmbH (Schnelldorf, Germany), all other substances were purchased from Merck Biosciences Ltd (Beeston/Nottingham, UK) (see Table 1 ).
Cell Culture and Experimental Design
Mouse ES cells (D3, ATCC CRL 1934) were stably transfected with the pαMHC-EGFP construct containing the gene of the EGFP under control of the α-MHC promoter as previously described [5] . To start differentiation, ES cells were trypsinised and cultured in 6 cm Petri-dishes (Greiner, Darmstadt, Germany) in suspension (2x10 6 cells/ml) on a rocking table (GFL 3006, GFL, Braunschweig, Germany) in Iscove's modified Dulbecco's Medium (IMDM) with 20% FCS, nonessential amino acids (0.1 mM) and β-mercaptoethanol (0.1 mM) (Invitrogen, Karlsruhe, Germany) at 37°C, 5% CO 2 , 95% humidity for 24 h to form EBs. About fifty EBs were transferred to each well of bacterial 6 well plates (Greiner, Darmstadt, Germany) and test compounds were added at the concentrations indicated in the figures. Each compound concentration was tested in triplicates in three individual experiments. On day five, half of the medium was replaced by fresh medium and fresh test compounds were added. EBs were monitored during the differentiation process using a fluorescent microscope (Axiovert 100 M, Zeiss, Jena, Germany) with a FITC filter set (AF Analysentechnik, Stuttgart, Germany) and x10 or x20 objectives. On day 14, EBs of each well were counted, washed twice in 5 ml PBS (Invitrogen), lysed in lysis buffer (20mM TrisHCl/0.5% Triton X 100) and fluorescence in the lysates was measured using a Tecan Safire® (Tecan, Crailsheim, Germany) at an excitation wavelength of 476 nm and an emission wavelength of 508 nm (Fig. 1) . Addtionally, protein content in lysates was measured using a standard Bradford TM Protein Assay (Coomassie Plus Reagent, Pierce, Rockford, IL) and a BSA protein standard (Sigma-Aldrich, Taufkirche, Germany). Fluorescence values were normalized either to 1 EB or to protein content (µg/ml) and expressed as percent of control values (vehicle only). Both, a significant decrease and a significant increase of values, compared to vehicle controls, represent an effect on cardiomyogenesis.To determine an EC 50 for Verapamil and Cyclosporin, 5 concentrations ranging from 1 nM to 10 µM were used. The obtained values were linearly interpolated between adjacent points, and the first concentration -starting from the lowest -to exceed an effect of 50% was determined as the EC 50 .Alternatively, on day 7, single EBs were plated in each well of 24 well tissue culture plates (Becton Dickinson, Heidelberg, Germany) and medium and compounds were added as described above. Photomicrographs of representative EBs were taken on day 14 using the Zeiss Axiovert with a FITC filter set. Representative expression of EGFP in ES cell derived cardiac cells treated with 10 µM Verapamil is shown in Fig. 1 .
To determine the time point of differentiation at which Verapamil and Cyclosporin A promote cardiomyogenesis, a time-staggered protocol was established as indicated in Fig. 5 . Briefly, compounds were added to EBs either in suspension or plated on 24 well plates as described above at 4 different time points (day 1, 3, 5, and 7) for 48 h. After incubation with the compounds, EBs were washed twice with differentiation medium and were further cultured in differentiation medium without compounds until quantification of cardiomyocytes on day 14. To clarify if inhibition of cardiomyocyte development seen by some compounds is due to a pure cytotoxic effect, the standard cytotoxicity test, the sodium 3'- tetrazolium] bis (4-methoxy-6-nitro) benzenesulphonic acid (XTT) test [6] was performed for an inhibitory and a promoting compound using ES cells from the same clone. Cells were seeded in 96 well plates and compounds were added at day 1. At day 10, XTT (Biotium Inc. Hayward CA) was added and Formazane absorbance was measured at 475 nm. Results are expressed as % inhibition compared to control values (vehicle only).
Semi-quantitative RT-PCR analysis
Total RNA was extracted from treated EBs using Qiagen Rneasy miniKit (Qiagen GmBH, Hilden, Germany). The preparation quality was assessed by agarose-formaldehyde gel electrophoresis. A total of 2 µg RNA was treated with DNase I (Amplification grade, Invitrogen Life Technologies, Carlsbad, CA, USA) before reverse transcription into cDNA by SuperscriptTM II Rnase H-free Reverse Transcriptase (Invitrogen) using random hexamer priming according to the manufacturer's instructions. PCR amplification of individual cDNAs was accomplished in 20 µl reactions containing 10 µl JumpStart REDTaq ReadyMix (Sigma, St.Louis, USA), 1 µl of synthesized cDNA and primers at a final concentration of 0.3µM each. All amplifications were performed using PCR Cycler (Eppendorf Mastercycler) under optimized conditions for each target sequence. PCR analysis was performed using specific primer pairs (see table 2) for genes of interest normalized against the housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), according to the following conditions: an initial step of 94°C for 2 min followed by 25-30 cycles of 94°C for 35 sec, 60°C for 45 sec, 72°C for 45 sec, and a final extension of 72°C for 10 min in a thermal cycler (Eppendorf Mastercycler). The RT-PCR products were analyzed by gel electrophoresis.
Statistical analysis
Analysis was done by the ANOVA test. Values of p<0.05 were considered to be statistically significant.
Results and Discussion
In our recent work we focused on the development of strategies for the specific differentiation of ES cells into early cardiomyocytes and for specific cardiac lineage selection [7] . Identification of factors and signalling cascades promoting selective generation of cardiac cells from embryonic stem cells is essential for the generation and isolation of large numbers of cardiomyocytes in vitro as well as for understanding cardiac development in vivo. Table 1 shows an overview of the small molecules identified in the present study as either promoting or inhibiting cardiomyogenesis. In the first set of experiments, 33 small molecules belonging to different cell signalling pathways were tested in parallel to investigate their effects on cardiomyogenesis according to the protocol as described in Figure 1 .
Cytosolic Ca
2+
is an universal signalling molecule involved in the regulation of various physiological and cellular processes such as contraction, cell motility, metabolism, gene expression, proliferation and apoptosis [8] . Therefore, we investigated the effects of different intracellular Ca 2+ -modulating compounds on the generation of cardiomyocytes from ES cells. Figure 2A shows the effects of cytosolic Ca 2+ modulating compounds on the process of cardiomyogenesis in the ES cell system. Treatment of EBs with 100 nM and 10 nM Ryanodine resulted in a significant 50% and 75% increase of the EGFP fluorescence, respectively, compared to untreated cells (=100%). Interestingly, treatment of EBs with 10 µM Verapamil caused a pronounced 94% increase of the EGFP fluorescence. The EC 50 (concentration causing a 50 % effect) determined from a dose-response curve [14] did not show any effect on cardiomyogenesis ( Fig. 2A) .
The effects of small molecules belonging to the Figure 2B . Exposure of cells to 2 µM Genistein, a general inhibitor of tyrosine kinases acting through a competitive inhibition with respect to ATP [15] , resulted in a 30% decrease of the EGFP fluorescence. PD 98059, an inhibitor of the p42/p44 MAP kinase ERK 1/2 [16] , and 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one (CFPDP), a p38 MAP Kinase inhibitor [17] , did not influence cardiomyogenesis. A slight increase of 36% was observed after treatment of EBs with 10 µM 1,2-Dimethyl-6-(2-thienyl)-imidazolo [5, 4-g] quinoxaline (Tyrphostin AGL 2043), a potent selective ATP-competitive and reversible inhibitor of PDGFβ-receptor [18] . To identify growth factors promoting cardiac development we recently established a new differentiation protocol using a defined serumreplacement medium (SRM) in combination with Dulbecco´s Modified Eagle Medium (DMEM). Using SRM/DMEM, we obtained an increase of α-MHC in relation to 0,2% foetal calf serum (FCS)/DMEM. Stimulation of EBs with PDGF-BB in the presence of SRM/DMEM resulted in a further enhancement in comparison with the SRM/DMEM-induced increase of α-MHC. Under these conditions, stimulation of the cells with 10-20% foetal calf serum totally repressed expression of α-MHC [19] . In the present study FCS has been used in all differentiation steps. Using the protocol described in Figure 1 , 50 ng/ml PDGF-BB had no effect on cardiomyogenesis since FCS was available in the medium during all differentiation steps. Under serum containing conditions, it is not possible to identify a cardiomyogenic effect of PDGF-BB and probably of other growth factors. This phenomenon is well known also by proliferation studies. A proliferative effect of PDGF-BB can only be detected in the absence of serum and after serum starvation for at least 24 hours. The slight stimulatory effect of Tyrphostin AGL 2043 might be explained by possible side effects of this molecule. 10 µM α-Cyano-(3,4,5-trihydroxy)cinnamonitrile (Tyrphostin A25), a competitive inhibitor of the tyrosine phosphorylation of the epidermal growth factor receptor [20] , caused a 50% reduction of cardiomyogenesis. Similarly, α-Cyano-(3,4-dihydroxy)-N-benzylcinnamide (Tyrphostin B42), another inhibitor of the tyrosine phosphorylation of the epidermal growth factor receptor [21] , also caused a reduction of the amount of cardiac cells. These results suggest that tyrosine kinases receptors, especially the EGF receptors, are involved in the differentiation of ES cells towards cardiomyocytes. In this context, it has been shown that Neuregulin, a member of the EGF family, is involved in cardiac development in vivo [22] .
Notably, exposure of EBs to 10 µM and 1 µM Cyclosporin A caused a 140% and 60% increase of the EGFP fluorescence, respectively. The EC 50 determined from a dose-response-curve covering concentrations between 1nM and 10µM was 0.36 µM. Cyclosporin A is an amino acid cyclic peptide used as an immunosuppressant compound. Complexes of Cyclosporin A with the immunophillin Cyclophilin A within -and calmodulin-dependent protein phosphatase 2B (Calcineurin) [23, 24] . Transcription factors of the NF/AT family, which act as substrates for Fig. 3 . Effects of Verapamil (10 µM) and Forskolin (400 nM) on the Expression of EGFP normalized to the number of EBs or to the protein content as well as on the formazan formation as a marker of the viability of the cells. Differentiation, addition of test compounds, and quantification of cardiac cells by EGFPexpression has been performed as indicated in Fig. 1 . Values from three independent experiments (mean ± SD, n=3), each performed in triplicates, were expressed as percent of control values (vehicle) (=100%). Both, a significant increase (*P<0.05) and decrease (P**<0.05) of values, compared to vehicle controls, represent an effect on generation of cardiac cells.
Calcineurin, are therefore also inhibited by Cyclosporin A. Interestingly, there is increasing evidence that Calcineurin is also involved in the regulation of other cellular processes such as apoptosis, embryonic development, and cancer [8, [24] [25] [26] [27] , as well as cardiac valve formation and cardiac hypertrophy [28, 29] . Figure 2C shows the effects of small molecules belonging to the "phospolipase and protein kinase" category. Staurosporine at a concentration of 100 nM caused cell death suggesting a general toxic effect of Staurosporine. Phorbol-12-myristate-13-acetat (PMA), one of the most commonly-used phorbol ester, activating protein kinase C (PKC) in vivo and in vitro [30] at a concentration of 100 nM, induced a 40% decrease of cardiomyogenesis whereas Calphostin C, a highly specific inhibitor of PKC [31] , caused a weak increase of cardiomyogenesis at a concentration of 10 nM. These findings suggest that the activation of PKC may be a negative regulator of cardiomyogenesis. In agreement with our findings, it has been shown recently that differentiation of embryonic stem cells into beating cardiomyocytes is dependent on down regulation of the PKCβ and PKCζ isoforms [32] . As shown in Figure 2C , 100 nM Calphostin did not influence the EGFP expression. This finding suggest that Calphostin C at higher concentrations than 10 nM might exerts effects counteracting the cardiac promoting effects of this molecule. Recently, Ventura et al. [33] reported that 1 µM Calphostin completely inhibited cardiac differentiation. However, since we observed a slight increase of cardiogenesis only at a concentration of 10 nM, effects seen at higher concentrations (e.g. inhibition of cardiac differentiation observed by Ventura et al.) may be attributed to side effects occurring at such concentrations. Mastoparan is a cell-permeable peptide directly activating G i and G o and in less extent G s pertussis toxin-sensitive G-proteins [34] . 1-[6-(17β-3-Methoxyestra-1,3,5 (10) -mobilizing pathways in various cell types [35] . However, neither Mastoparan nor U-73122 had an effect on cardiomyogenesis in ES cells suggesting a minor role of these pathways for cardiomyogenesis.
Arachidonic acid, generated by the Phospholipase A2-induced hydrolysis of the membrane phospholipids, is a precursor for prostaglandins, prostacyclin, and thromboxane [36] . Ibuprofen and Diclofenac are competitive inhibitors of cyclooxygenase (COX)-1 and COX-2, which are enzymes of the eicosanoid metabolism using arachidonic acid as substrate [37] . As shown in Fig. 2D , neither arachidonic acid itself nor the cyclooxygenase inhibitors had any effects on cardiomyogenesis.
As demonstrated in Figure 2E , treatment of EBs with 100 nM Testosterone and 100 nM 17β-Estradiol resulted in a weak 30% increase, whereas Dexamethason at 100 and 10 nM caused a moderate 30% decrease in EGFP fluorescence. The biological actions of the sex hormones testosterone and 17β-Estradiol are predominantly exerted through binding to the nuclear steroid receptors that function as ligand-activated transcription factors [38] . However, sex hormones are also able to stimulate various signal transduction pathways such as kinase-signalling cascades via receptors located in the plasma membranes [38] . Our findings demonstrate that both testosterone and 17β-estradiol had only a weak effect on cardiomyogenesis in ES cells. In contrast, Dexamethasone, a chemically synthesized corticoid, inhibited cardiomyogenesis in ES cells. Dexamethasone belongs to the glucocorticoids that are potent antiinflammatory drugs acting through binding to a specific glucocorticoid receptor (GR) [39] .
Results from treatment of EBs with compounds belonging to neurotransmitters and cAMP -increasing compounds are shown in Fig. 2F . Forskolin (4 µM), which is an adenylate cyclase stimulator increasing intracellular cAMP [40] , significantly reduced cardiomyogenesis by 50%, whereas Isoproterenol, a β-adrenergic agonist that stimulates adenylate cyclase activity [41] , did not influence cardiomyogenesis. Carbachol (1 µM), an activator of the muscarinic acetylcholine receptors [42] , and histamine (1 µM), which is a neurotransmitter acting through various histamine receptors [43] , also inhibits cardiomyogenesis by 30% and 35%, respectively. Serotonin, another neurotransmitter acting through various subtypes of specific 5HT-receptors [44] , caused a 52% increase of EGFP fluorescence at 1µM. In this context, there is an evidence that serotonin may play a role in cardiac morphogenesis [45] .
Treatment of EBs with the flavonoids antioxidant compounds Apigenin [46] , Epigallocatechin Gallate (EGCG) [47] and the glycolipid gangliosides GM1, each at a concentration of 10 µM, resulted in a 47%, 21% and 30% decrease of EGFP fluorescence, respectively (Fig.  2G) . However, the anti-cardiomyogenic activity of Apigenin was more pronounced than that of EGCG. These results are supported by findings demonstrating that Fig. 4 . Effects of Verapamil and Cyclosporin A on the expression of Nkx2.5, GATA4 and Troponin T. A, Addition of Verapamil or Cyclosporin A (each 1 µM) was performed in medium containing 1-day old EBs and RNA was isolated at different time points according to the above protocol. B, To determine the expression of Nkx2.5, GATA4 and Troponin T, total RNA was isolated from EBs and RT-PCR has been performed using the appropriate primers (see table  2 ). One experiment from two independent experiments with similar results.
Fig. 5. Effects of Verapamil and Cyclosporin A on the expression of Nestin and NF-H. A, Addition of Verapamil or
Cyclosporin A (each 1 µM) was performed in medium containing 1-day old EBs according to the protocol as described in Figure  4 . To determine the expression of Nestin and NF-H, total RNA was isolated after 1 and 8 days from EBs and RT-PCR has been performed using the primers and conditions as described in table 2. A (each 1 µM) . Stimulation has been performed according to the protocol as described in Figure 1 . On day 14, EBs on each plate were counted, lysed and fluorescence in the lysates was measured at an excitation wavelength of 476 nm and an emission wavelength of 508 nm. Values from three independent experiments (mean ± SD),each performed in triplicates, were expressed as percent of control values (vehicle) (=100%). Values are normalized to the number of EBs. A significant increase of values (*P<0.05), compared to vehicle controls, represent an effect on generation of cardiac cells. No statistical differences were observed between the effect (Verapamil + Cyclosporin) versus Verapamil or Cyclosporin alone.
incubation of EBs with H 2 O 2 enhances cardiomyogenesis, whereas radical scavengers exerted inhibitory effects [48] . Also, like EGCG [47] , the glycolipid Ganglioside GM1 that is able to trap growth factors such as PDGF [47] , exerted anti-cardiomyogenic effects. Finally, the Cl -channel blocker NPPB [14] (100 nM) induced a 50% increase of cardiomyogenesis suggesting a possible role of the Cl -channel in cardiomyogenesis whereas tetrodotoxin (TTX), a blocker of the voltage dependent Na + channel [14, 49] at a concentration of 100 nM resulted in a weak decrease of 15% (Fig. 2H) .
To clarify if compounds showing an inhibitory effect on cardiomyogenesis are cytotoxic, a sodium 3'-[1-phenylaminocarbonyl-3,4-tetrazolium] bis (4-methoxy-6-nitro)benzenesulphonic acid (XTT) cytotoxicity assay was performed for one potent inhibiting (Forskolin) and one promoting compound (Verapamil). As shown in Figure 3 , no cytotoxicity was observed at concentrations used in the present study. Also, EGFP fluorescence in cell lysates was not only normalized to number of EBs, but also to protein content of cell lysates, since a cytotoxic or mitogenic action of a compound would influence the size of the EBs. As demonstrated in Fig. 3 , both calculations gave similar results. These findings demonstrate that the inhibitory effects of Forskolin can not be attributed to a possible toxic effect of Forskolin. However, possible toxic effects of other molecules used in this study such as Tyrphostin A25 can not be excluded.
To demonstrate whether the cardiomyogenic effect of Verapamil and Cyclosporin A determined at day 14 ( Fig. 2, 3 ) is accompanied by an increased expression level of the cardiac specific transcription factors GATA4 and Nkx2.5 [7] , the expression level of GATA4 and Nkx2.5 has been determined after stimulation of 1-day old EBs (Fig. 4) .
Compared to vehicle-treated EBs, an increase in the expression of NKx2.5 and GATA4 was found only after 1 day of stimulation with 1µM Cyclosporin A (Fig. 4) . Even after 8 days, no increase in the expression level of Troponin T could be observed. In contrast, after stimulation with 1 µM Verapamil, an increase in the expression level of Nkx2.5 could be observed only at day 8. This effect was accompanied with an increase in the expression level of Troponin T (Fig. 4 ). These findings demonstrate that the mode of action of both compounds seems to be different, although leading to the same effect (increase in the amount of cardiac cells). The detailed mechanisms by which both agonists exert their effects remain to be elucidated.
In parallel, we determined the expression of the neuronal cell specific genes Neurofilament H (NF-H) and Nestin. As shown in Figure 5 both agonists had no effect on the expression of Nestin. Only a weak decrease of the expression of NF-H was observed by Cyclosporin A. To test whether an additive or synergistic effect can be observed, Cyclosporin and Verapamil were added together (both at 1 µM ) using the protocol described in Figure 1 . In 3 individual experiments, no statistically (Verapamil or Cyclosporine A effect versus Verapamil plus Cyclosporine A effect) synergistic or additive effect of the combinational treatment can be observed ( Figure 6 ) suggesting that the compounds exert their effect at different points of the differentiation pathways.
In shown in Fig. 7A . EGFP fluorescence was determined by fluorescence spectroscopy or by microscopy at day 14. Although in the screening study maximal effects were observed at 10 µM, both agonists were used at a concentration of 1 µM in these experiments to avoid possible side effects. As demonstrated in Fig. 7B , the addition of 1 µM Verapamil resulted in an increase of cardiomyogenesis only if the compound was added on day 1. No promoting effect of Verapamil was observed if the compound is added at the other time points (day 3, 5, or 7) for 48 h. In accordance with these findings, a parallel increase of the expression of the α-MHC and EGFP mRNA was observed. Similar results were observed after addition of 1 µM Cyclosporin A (Fig. 7C) . Again, only the addition of 1 µM Cyclosporin A at day 1 resulted in an increase of cardiomyogenesis that correlated with an increase of α-MHC and EGFP mRNA expression. The expression of PECAM-1 mRNA as a marker for endothelial cells and of α-smooth muscle actin (α-SMA) mRNA as a marker for SMC was not increased channel, whereas Cyclosporin A inhibits Calcineurin and NF/AT transcription factors [28, 29] . It is known that constitutive active Calcineurin leads to cardiac hypertrophy, and that a certain subtype of NF/AT is crucial for correct cardiac valve formation [28, 29] .
Our results suggests that the generation of early cardiac progenitors is correlated to Ca 2+ signalling and the Calcineurin pathway and that inhibition of both signalling pathways at different levels resulted in an increased capacity of ES cells to differentiate into cardiomyocytes. Since both agonists had no effect on the expression of PECAM-1, α-SMA, NF-H and Nestin, Verapamil and Cyclosporin A induce preferable cardiomyogenesis. Although we succeeded in identification of a distinct signal transduction pathway promoting cardiomyogenesis, the detailed intracellular mechanisms of the agonists remain to be elucidated in further studies.
